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from 2006 to 2008 in 72 ICUs in 14 European countries. A total of 779 patients (62.5% males, median age 63 years) with IC were included.
The median rate of candidaemia was 9 per 1000 admissions. In 10.8% the infection was already present at the time of admission to ICU.
Candida albicans accounted for 54% of the isolates, followed by Candida parapsilosis 18.5%, Candida glabrata 13.8%, Candida tropicalis 6%,
Candida krusei 2.5%, and other species 5.3%. Infections due to C. krusei (57.9%) and C. glabrata (43.6%) had the highest crude mortality
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was more often isolated after abdominal surgery in patients 60 years, and C. parapsilosis was more often isolated in neurosurgery and
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ratio (HR) 1.9, p 0.001), central venous catheter (HR 1.8, p 0.05), corticosteroids (HR 1.5, p 0.03), not receiving systemic antifungal
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TABLE 1. European Confederation of Medical Mycology
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prospective study of Candida infections in 779 surgical
patients in ICU from 14 countries
Country Cases (%) Country Cases (%)
Austria 97 12.5 Italy 216 27.7
Czech Republic 77 9.9 the Netherlands 18 2.3
Finland 10 1.3 Portugal 6 0.8
France 55 7.1 Spain 96 12.3
Germany 13 1.7 Sweden 101 13.0
Greece 41 5.3 Turkey 11 0.4
Hungary 5 0.6 UK 33 4.2Invasive candidosis (IC) has a significant impact on morbidity,
mortality, length of hospital stay, and healthcare costs in criti-
cally ill patients [1]. The overall mortality for these patients is
high. Candidaemia increases mortality rates in the range of
20–49% [2] and the attributable mortality has been calculated
to be around 15% [3].
A nationwide US surveillance study demonstrated that the
crude mortality rate of IC was 47% for patients in intensive
care units (ICUs) and 29% for patients in a hospital ward [4].
In a multicentre study of ICUs in France from 2005 to 2006,
the mortality associated with IC in ICUs was also high (45.9%)
[5].
In a previous European Confederation of Medical Mycology
(ECMM) prospective multinational study performed in seven
European countries, the rates of candidaemia ranged from 0.20
to 0.38 per 1000 hospital admissions [6]. Intensive care treat-
ments accounted for about 40% of all episodes of candidaemia
in various surveys conducted in Europe [2,6,7]. Moreover, two
recent European studies documented the significance of fungal
diseases in the intensive care setting [8,9].
Although Candida albicans is still the main cause of IC, a shift
towards non-albicans species in some patients and age groups
has been observed over the past two decades [10,11].
Numerous large surveillance studies have provided important
information regarding the epidemiology of candidaemia. How-
ever, information in particular on surgical patients in ICU re-
mains scarce. Therefore, the ECMM initiated a prospective
multicentre survey on IC in surgical patients in ICU.
The aims of the survey were to expand our knowledge of the
characteristics of surgical patients with IC in ICU to understand
the epidemiology of IC and to determine which factors are
associated with mortality.MethodsStudy design and patients
ECMM survey in surgical patients in ICU with invasive candi-
dosis was a prospective, multicentre, observational laboratory-
based study. Patient recruitment began in 2006 (in France and
Turkey, 2007) and concluded on 31 December 2008 (Table 1).
Fourteen countries participated. Each country had a national
coordinator who collaborated with colleagues in ICU. Surgical
ICU patients with IC were eligible for enrolment. In each case, a
standardized questionnaire was filled out by clinicians and by
microbiologists in the mycology laboratories. Each patient was
assigned a code number by the national coordinator (theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectpatient’s name and birth were removed) before sending the
questionnaire to the coordinator for the whole study. Local
ethical committee approval at each participating centre was
expedited but no approval was required owing to the purely
observational nature of the study.
The aim was to include 50–75 patients per country to be
able to include at least 800 patients.
Inclusion criteria
All surgical patients in ICU who had a microbiologically docu-
mented IC were included in the study, and data were recorded
regardless of whether they had IC at admission or developed it
during their stay in ICU.
Clinical data
Invasive candidosis with or without candidaemia were defined
by a culture positive for Candida obtained from blood or other
normally sterile body sites, according to the EORTC/MSG
criteria [12]. The infections were considered ICU-acquired
when diagnosed 48 hours after admission to ICU.
Collected data included demographic characteristics; type of
preceding surgery; risk factors and underlying diseases; diag-
nosis of fungal infection; index of severity of illness at admission
to ICU (APACHE II score); antifungal prophylaxis and treat-
ment; and outcome at day 30 after diagnosis of Candida infec-
tion (Table 2).
Data on removal of central venous catheters (CVCs) was
collected and culture results were documented. Patient
outcome at day 30 after detection of IC, time in ICU, and time
of hospital discharge were determined. Epidemiological data
concerning the ICU were collected, including number of ad-
missions and patient days.
Prophylactic antifungal therapy was defined as the adminis-
tration of an antifungal drug to a patient at high risk for Candida
infection but with no symptoms, signs, or laboratory confir-
mation of such infection. First-line therapy was defined as the
first antifungal drug given to the patient either as empirical
therapy or as therapy after a Candida-positive culture from a
sterile body site.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 87.e1–87.e10
TABLE 2. Demographic data and clinical characteristics of 779
surgical patients in ICU with invasive candidosis
Variable
Median:mean (range),
or n/x (%)
Age (years) 63:58.7 (0–91)
Gender (male) 487 (62.5)
Days of hospitalization before admission to ICU 2:15.2 (0–744)
IC present at admission to ICU 84/719 (10.8)
Days in ICU before IC 12:17.9 (0–190)
Rate of candidaemia per 1000 admissions to ICU 9:12 (3–28)
Total days in ICU 23:33 (0–329)
Candida colonization (within 2 weeks before IC) 234/400 (58.5)
Antifungal prophylaxis (within 2 weeks before IC) 129 (16.5)
Antifungal treatment 670/720 (93)
Type of preceding surgery
Abdominal 401 (51.5)
Thoracic 156 (20.0)
Vascular 49 (6.3)
Neurosurgery 64 (8.2)
Orthopaedic 12 (1.5)
Multiple trauma 54 (6.9)
Solid organ transplant 26 (3.3)
Other 17 (2.2)
Repeated surgery 166/752 (21.3)
Clinical characteristicsa
Pancreatitis 7 (0.9)
Solid tumour 178 (22.9)
Burns 9 (1.2)
Diabetes mellitus 118 (15.2)
Human immunodeficiency virus infection 0
Haematological malignancy 26 (3.3)
Rheumatological disease 23 (3)
Broad-spectrum antibiotics in the last 2 weeks 511 (78.4)
Steroid use in the last 2 weeks 176 (22.6)
Total parenteral nutrition 346 (44.4)
Dialysis at presentation 142 (18.2)
Invasive mechanical ventilation 468 (60)
Central venous catheter 776 (96.6)
Prosthetic devices 43 (5.5)
Outcome
Death 296/763 (38.8)
Abbreviations: IC, invasive candidosis; ICU; intensive care unit.
aMore than one factor may be present in a single case.
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Microbiological data, such as date and number of positive blood
cultures, blood culture system used, culture of intravascular
lines, presence of mucous membrane colonization, and yeast
species isolated were collected for each patient.
Identification of Candida isolates at species level was per-
formed in the microbiology laboratories of each institution
using standard methods.
Statistical analysis
Statistical analyses consisted of descriptive frequency tables and
Pearson’s chi-square or Fisher’s exact test for clinical and
mycological characteristics. Statistical significance was assumed
for a two-tailed p-value <0.05. Median and range were calcu-
lated as continuous variables. Incidence per 1000 admissions to
ICU was also calculated.
Multivariate survival analysis
To determine which factors were associated with mortality in
patients with IC, several approaches of multivariate survival
analysis using a proportional hazards method proposed by Cox
were conducted. The first approach was to fit the model withClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andall patients in the data set to study overall survival. The second
approach was to fit the same model with the patients infected
by a specific Candida species, for each species documented.
Survival time up to 30 days from the date of first positive
diagnosis of IC was calculated for each patient. All models
started by including a set of risk factors, underlying diseases,
type of preceding surgery, and background information as
covariates. Variables with the least influence on survival (p-
value >0.15) were excluded from the model one by one. Esti-
mates from the models were obtained as hazard ratios and the
associated 95% confidence intervals. All statistical analyses were
conducted using SAS 9.3 software and R version 2.10.1.ResultsPatient characteristics and episodes of infection
A total of 72 ICUs in 14 countries participated. A total of 807
patients were recruited, 28 of whom were subsequently
excluded from analysis because they did not fulfil the inclusion
criteria of having IC.
Of the 779 eligible patients included in the study, 42 were
<18 years old. The median duration of hospital stay before
admission to ICU was 2 days (mean 15.2 days, range 0–744).
Infection was present before admission to ICU in 84 (10.8%) of
the patients and occurred 48 hours after admission to ICU in
another 68 (8.7%) of the patients; it was considered ICU-
acquired (occurred 48 hours after ICU admission) in 627
(80.5%) of surgical patients. The total duration of stay in ICU
was median 23 days (mean 33 days, range 0–329 days). The
shortest stay was associated with Candida glabrata (median 18
days) and the longest with Candida parapsilosis (median 30 days).
Fifty-seven ICUs in nine countries reported all episodes and
could provide the total number of surgical admissions. Their
median rate of candidaemia was 9 (range 3–28) per 1000
surgical admissions to ICU.
Localization of invasive infection was as follows: 637 pa-
tients (81.8%) with isolated candidaemia; 126 (16.2%) with
candidaemia and with deep infection (Candida was isolated
using sterile technique from peritoneal fluid in 46 patients,
abdominal abscess in 42 patients, pleural fluid in eight patients,
various biopsies in seven patients, deep surgical wounds in six
patients, cerebrospinal fluid in four patients, bile in three pa-
tients, and various other normally sterile body fluids in ten
patients) and 16 patients (2%) with IC but without docu-
mented candidaemia.
In the latter 16 patients, a positive culture was obtained by
sterile means from the peritoneal fluid, oesophagus biopsy,
pleura, deep abdominal wound, abdominal abscess, and
mediastinum.Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 87.e1–87.e10
TABLE 3. Species distribution of 807 Candida isolates in 779
patients
Candida species Number of isolates (%)
C. albicans 436 54.0
C. parapsilosis 149 18.5
C. glabrata 111 13.8
C. tropicalis 49 6.0
C. krusei 20 2.5
C. lusitaniae 14 1.7
C. dubliniensis 9 1.2
C. guillermondii 5 0.6
C. ciferrii 4 0.4
Othera 9 1.2
Total 807 100
aC. pelliculosa, n = 3; C. haemoloni, n = 2; C. kefyr, n = 2; C. lambica, n = 1; C. humicola,
n = 1.
87.e4 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIAmong the 763 patients with candidaemia, the time from
ICU admission to first positive blood culture drawn was 5
days for 127 patients (22%). The time from ICU admission to
first positive blood culture was a median of 12 days (mean 17.9
days, range 0–190), with medians of 6 days for Candida krusei, 7
days for C. glabrata, 10 days for C. albicans and Candida tropicalis,
and 16 days for C. parapsilosis.
Concomitant bacteraemia was observed in 34 of 763 pa-
tients (4.9%) with candidaemia.
Of the affected patients, 62.5% were male and 37.5% were
female. The median age was 63 years (mean age 59 years, range
3 days to 91 years). Among the 779 surgical patients, 401 had
undergone abdominal surgery, 156 thoracic surgery, 49
vascular surgery, 64 neurosurgery, 54 multiple trauma, 26 solid
organ transplant (13 liver, six heart, three kidney, two lung, one
heart and liver, and one spleen and liver), and 29 other surgery.FIG. 1. Candida species (n = 807) distribution in 779 surgical patients in inte
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectRepeated surgical intervention was necessary in 166 patients
(21.3%) during their stay in ICU, mainly after previous
abdominal surgery (60%).
For the main clinical characteristics of the patients, see
Table 2.
Mycology data
In the 779 patients with IC a total of 807 isolates were iden-
tified. Candida albicans was isolated in 54% of cases, followed by
C. parapsilosis in 18.5%, C. glabrata in 13.8%, C. tropicalis in 6%,
C. krusei in 2.5%, and other species in 5.3%, see Table 3. If Spain
and Italy are excluded, C. glabrata ranks second most common.
Two or three different Candida species were found in 24 and
two patients, respectively.
Candida colonization cultures were taken in 51% of patients.
In 58.5% of them a Candida species was isolated, and the same
colonizing species was the cause of IC in 94.5% of these cases.
Candida parapsilosis was isolated more often in thoracic,
neurosurgical, solid organ transplant and multiple trauma pa-
tients compared with abdominal surgery patients. Abdominal
surgery patients had the highest rate of C. glabrata infections
(16.2%) compared with the other patient groups, and neuro-
surgical patients had the lowest rate (1.5%) (Fig. 1).
Of the 42 patients <18 years, 26were children1 year old. The
species distribution was C. albicans in 42.3% (n = 11), C. parapsilosis
in 38.5% (n = 10), C. glabrata in 7.7% (n = 2), C. tropicalis in 7.7%
(n = 2) and Candida guilliermondii in 3.8% (n = 1).
The prevalence of C. glabrata increased with patient age;
71.8% of the cases occurred in patients aged 60 years.nsive care units.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 87.e1–87.e10
TABLE 4. Results from multivariate survival analysis of all
patients with IC, in which records of line removed were
included (number of patients included was 418) or were
excluded (number of patients included was 719)
Risk factor
No. of
deaths
No. of
survivals
Hazard
ratio
95% hazard
ratio
confidence
limits p-value
Records of line removed included (n [ 418)
Age
Older than 60 years 97 150 1.91 1.30–2.80 0.001
60 years and younger 37 134 1.00
Type of infection
ICU-acquired infection 125 241 1.72 0.87–3.40 0.12
Infection prior to
ICU admission
9 43 1.00
Treatment
No 23 15 2.80 1.74–4.50 < 0.0001
Yes 111 269 1.00
Line removed
No 53 70 1.55 1.08–2.23 0.02
Yes 81 214 1.00
Corticosteroid
Yes 42 59 1.52 1.05–2.20 0.03
No 92 225 1.00
Total parenteral nutrition
Yes 83 150 1.34 0.94–1.90 0.11
No 51 134 1.00
CVC
Yes 122 229 1.84 1.01–3.34 0.05
No 12 55 1.00
Prosthetic device
Yes 16 16 1.64 0.96–2.80 0.07
No 118 268 1.00
Records of line removed excluded (n [ 719)
Age
Older than 60 years 166 258 1.98 1.48–2.66 < 0.0001
60 years and younger 62 233 1.00
Type of infection
ICU-acquired infection 209 390 2.10 1.31–3.37 0.002
Infection prior to
ICU admission
19 101 1.00
Treatment
No 39 31 2.91 2.06–4.12 < 0.0001
Yes 189 460 1.00
Corticosteroid
Yes 68 97 1.42 1.07–1.89 0.02
No 160 394 1.00
Total parenteral nutrition
Yes 122 207 1.38 1.06–1.80 0.02
No 106 284 1.00
CVC
Yes 198 373 1.47 0.99–2.18 0.05
No 30 118 1.00
Prosthetic device
Yes 19 21 1.51 0.94–2.43 0.09
No 209 470 1.00
Abbreviations: CVC, central venous catheter; ICU, intensive care unit.
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A total of 129 patients were receiving systemic antifungal pro-
phylaxis (16.5%) and developed a Candida infection. Patients
received fluconazole (78%), caspofungin (7.1%), voriconazole
(3.2%), liposomal amphotericin B (5.6%), amphotericin B deoxy-
cholate (3.9%), or other drugs (2.2%). For three patients the name
of the drug was not recorded. Of the 98 patients who received
fluconazole as prophylaxis, C. albicans was the cause of IC in 44%,
followed by C. parapsilosis in 27.6%. Candida glabrata and C. krusei
were isolated in 17.4% and 4.1% of patients, respectively.
Initial antifungal treatment
For 670 patients, the initial systemic antifungal drug was
recorded. Fifty patients received no treatment, and for 59 pa-
tients the data were not recorded.
Fluconazole, administered to 60% (402 of 670) of the pa-
tients, was the antifungal most frequently used to treat Candida
infection, followed by caspofungin (125 patients, 18.7%), lipid-
based amphotericin B (87 patients, 13%), voriconazole (32
patients, 4.8%), and various other drugs (24 patients, 3.5%).
Interventions associated with antifungal treatment
Survival with lines removed or not removed was recorded for
411 out of 779 patients. The vascular catheter was removed or
changed upon diagnosis of candidaemia in 288 of 411 patients
(70%). The survival rate was 68.1% for patients from whom the
lines were removed, compared with 48.8% (p 0.02) in patient
with lines not removed (Table 4).
Outcome
The overall crude mortality at day 30 was 38.8% (same in males
and females). In the 11 infants 3–12 months old the mortality
was 72.7%; if the four infants <3 months old are included, the
mortality was 67%.
APACHE II scores were recorded for 197 patients. APACHE
II score >20 was recorded for 100 patients and 49 (49%) of
these patients died. Of the 97 patients with APACHE II score
20, 15 (15.5%) died.
Infections caused by C. krusei and C. glabrata had the highest
crude mortality rates (57.9% and 43.6%, respectively)
compared with C. tropicalis (26.8%), C. albicans (36.8%), and
C. parapsilosis (36.2%).
Multivariate survival analysis of factors associated with
death for various infections
Table 4 shows the results of multivariate analysis of factors asso-
ciated with death in surgical patients with IC in ICU. In the first
approach the model was applied to all patients and in the second
themodel was applied excluding information on catheter removal.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andCandida albicans infection
When analysis excluded data records of whether lines were
removed or not, the results were almost the same except that
patients without treatment were at much higher risk (hazard
ratio 3.2, p <0.0001) and CVC was no longer a statistically
significant factor at the 5% level (Table 5). One major dif-
ference was that patients with repeated surgery had a lower
risk of dying (hazard ratio 0.6, p 0.01).Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 87.e1–87.e10
TABLE 5. Results from multivariate survival analysis of
patients infected by Candida albicans, Candida glabrata and
Candida parapsilopsis where records of line removed were
included
Risk factor
No. of
deaths
No. of
survivors
Hazard
ratio
95% hazard
ratio
confidence
limits p-value
Results for C. albicans (number of patients included was 230)
Age
Older than 60 years 54 82 1.84 1.12–3.02 0.02
60 years and younger 23 71 1.00
Type of infection
ICU-acquired infection 73 126 2.98 1.08–8.21 0.04
Infection prior to ICU 4 27 1.00
Treatment
No 12 10 2.14 1.12–4.07 0.02
Yes 65 143 1.00
Line removed
No 33 42 1.72 1.08–2.73 0.02
Yes 44 111 1.00
Repeated surgical
Yes 12 45 0.43 0.23–0.81 0.01
No 65 108 1.00
Corticosteroid
Yes 27 32 1.88 1.17–3.02 0.01
No 50 121 1.00
CVC
Yes 70 118 2.63 1.20–5.75 0.01
No 7 35 1.00
Results for C. glabrata (number of patients included was 95)
Age
Older than 60 years 28 37 2.25 0.91–5.56 0.08
60 years and younger 6 24 1.00
Treatment
No 8 3 5.75 2.35–14.04 0.0001
Yes 26 58 1.00
Total parenteral nutrition
Yes 19 22 2.67 1.28–5.55 0.01
No 15 39 1.00
Results for C. parapsilosis (number of patients included was 131)
Age
Older than 60 years 26 36 1.90 0.99–3.66 0.05
60 years and younger 14 55 1.00
Treatment
No 8 7 2.89 2.89–6.31 0.01
Yes 32 84 1.00
Abbreviations: CVC, central venous catheter; ICU, intensive care unit.
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The results shown in Table 5 are from the model that included
all patients infected by C. glabrata and C. parapsilosis. Information
about patients’ catheters was excluded because it did not have
any influence on survival.DiscussionThis ECMM study is to our knowledge one of the few large
prospective studies on IC carried out exclusively on surgical
patients in ICUs.
The median rate of candidaemia, calculated for 57 ICUs from
nine countries, was 9 per 1000 surgical admissions to ICU,
consistent with the Bougnoux prospective multicentre study of
surgical patients in ICU with candidaemia [13]. However, our
range (3–28) was wide. Finland had the lowest rate, while Italy
and Spain had the highest. In recent point prevalence studies, aClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcandidaemia incidence of 6.9 per 1000 ICU patients was re-
ported [14]. However, that study also included both medical
and surgical patients.
Candida albicans accounted for 54% of invasive isolates, fol-
lowed by C. parapsilosis for 18.5%, C. glabrata for 13.8%,
C. tropicalis for 6%, C. krusei for 2.5%, and other species 5.3%.
Compared with other studies, a high incidence of C. parapsilosis
was recorded—the incidence is usually around 7–13%.
Concomitant bacteraemia was observed in 5% of cases, and in
3.7% more than one Candida species was isolated from blood.
This is consistent with Jensen et al. [15], who recently reported
that among 530 episodes of candidaemia, 2.8% had mixed
candidaemia.
The species distribution in this study also showed geographic
differences. Candida albicans was the most common Candida
species. In southern Europe, C. parapsilosis ranked second and
C. glabrata third in frequency, whereas in northern Europe,
C. glabrata ranked second and C. parapsilosis third. These
geographic differences have been described before [16,17].
The median duration of hospital stay before admission to
ICU was short at 2 days, and the median total stay in ICU was
23 days. The majority (80.5%) of surgical patients developed an
ICU-acquired infection 48 hours after ICU admission. Of this
majority, 98% presented with candidaemia a median of 12 days
after ICU admission.
However, time in ICU to first positive blood culture varied
with the species, being shortest for C. krusei and C. glabrata
(median 6 days and 7 days, respectively) and longest for
C. parapsilosis (16 days), with C. albicans between (10 days). In
only 22% of patients did candidaemia occur within 5 days after
ICU admission. Although this percentage is lower than has been
previously reported by ICUs [5], the fact that 22% of patients
developed candidaemia < 5 days after ICU admission suggests
that Candida species such as C. glabrata and C. krusei should be
taken into account in empirical antimicrobial therapy, even in
cases of sepsis occurring early during ICU stay.
The predominance of abdominal (51.5%) and thoracic (20%)
pathologies underlying candidaemia, age 60 years, and males
(62.5%) in our patient group is emphasized by the data in
Table 5. Male gender seems to be a risk factor. This is consis-
tent with other reports [16,17].
The incidence of C. glabrata infection was greater in patients
after abdominal surgery (16.2%) compared with patients after
thoracic surgery (9.9%), multiple trauma (8.8%) and neurosur-
gery (1.5%). Infection with C. glabrata was also associated with
older age, which has been reported previously [16,17]. This
might reflect the fact that colonization of the gastrointestinal
tract with C. glabrata increases with older age [17,18]. Incidence
of C. parapsilosis infection in patients after abdominal surgery
was lower (12.4%) compared with neurosurgery (40.3%) andious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 87.e1–87.e10
CMI Klingspor et al. Invasive candidosis in surgical patients in ICUs 87.e7multiple trauma (35.1%). Candida parapsilosis can be isolated
from the patients’ skin, the hands of healthcare workers, and
the hospital environment and is associated with colonization of
catheters.
This could explain the high rate in multiple trauma patients
with broken skin barriers, but the high rate in neurosurgery
patients has yet to be elucidated. One reason may be inade-
quate infection control measures in some ICUs. Furthermore,
GISIA-3 data highlight an association between parenteral
nutrition and C. parapsilosis [19]. Age also seems to determine
predisposition to different Candida species. In children 1 year
old C. parapsilosis was isolated in 38.5% of cases, while
C. glabrata was rarely isolated. This finding is consistent with a
recently published global study on neonates [20].
Patients with candidaemia frequently have a CVC in place, as
was the case in 97% of the patients in this ECMM survey.
Recent guidelines for the management of candidosis strongly
recommend early CVC removal in all non-neutropenic patients
with candidaemia [21,22] and in patients with CVC-related
candidaemia [23].
In this ECMM study, CVC removal was significantly associ-
ated with survival compared with maintained CVC. The results
of Leroy et al. and Tortorano et al. were similar (39.4% versus
60.9% and 39% versus 53%, respectively) [5,7]. Catheter
removal has been associated with an improved probability of
survival in other studies as well [24,25]. However, in our
multivariate analysis CVC removal after candidaemia with
C. glabrata and C. parapsilosis did not have a significant impact on
survival, in contrast to C. albicans infections. Culture from the
catheter tip was recorded in this study in only 284 (36.5%)
cases. Candida albicans was the most common species (60.6%)
isolated from the catheters, followed by C. parapsilosis (15.8%),
C. tropicalis (12.8%), and C. glabrata (7.9%). In a recent scanning
electron microscopy study [26] including 172 patients, yeasts
were detected in significantly more catheters obtained from
men than from women (p <0.01). This is inconsistent with the
results of this ECMM study. The percentages of women and
men with an infected catheter were almost the same, 58.8% and
58.1%, respectively. This variation between the two studies
emphasizes the need for further investigation of the prevalence
of Candida species biofilms in catheters.
According to several studies, only 5–15% of patients are
colonized by Candida species at admission to ICU, but this
progressively increases with time to 50–80% [27,28]. Growing
evidence suggests that monitoring of Candida colonization in
surgical patients and clinical prediction rules based on combined
risk factors may be used to identify ICU patients at risk of IC
[27,28]. In this ECMM study, monitoring of Candida coloniza-
tion was recorded for only 51% of cases. Even so, in investi-
gated patients, except for 4.3%, the colonizing species was theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andsame species that later caused IC. In 1.2% the colonizing species
together with another Candida species caused IC.
Eggimann et al. [29] conducted a randomized, placebo-
controlled trial to study the efficacy of fluconazole prophylaxis
among 49 high-risk surgical patients with recurrent gastrointes-
tinal perforations or anastomotic leakages. They reported that
patients who received fluconazole were less likely to have
abdominal colonization or infection (peritonitis) with Candida
species, but they were unable to assess whether the prophylaxis
affected the risk of acquiring candidaemia because of the small
number of patients enrolled. According to recent European
guidelines prophylactic usage of fluconazole is recommended in
patients with recent abdominal surgery and recurrent gastroin-
testinal perforations or anastomotic leakages [22]. However,
local epidemiologywithC. glabrata andC. kruseimust be regarded.
In our study, a total of 129 patients (16.5%) receiving sys-
temic antifungal prophylaxis developed IC. Fluconazole was
given as prophylaxis in 98 patients. In 44% of the patients
C. albicans was the cause of IC, followed by C. parapsilosis in
27.6%. Species with known intrinsic resistance to azoles were
over-represented in the breakthrough cases compared with the
whole population. Candida glabrata and C. krusei were isolated in
17.4% and 4.1%, respectively.
Candidaemia is associated with significant morbidity [10].
Delay of therapy for candidaemia beyond 12 hours after blood
sampling has been associated with an increase in in-hospital
mortality from <20% to 40% [30].
In this study 93% of the patients with IC received treatment.
Our data shows that patients who did not receive systemic
antifungal treatment for IC ran a significantly higher risk of dying
(p <0.0001).
Recent data suggest that echinocandins should be used as the
first choice because overall survival of patients with candidae-
mia is improved. The recommendation for fluconazole is rec-
ommended with marginal strength only, except for
C. parapsilosis [22].
In this ECMM study focused on surgical patients in ICUs,
mortality was a median of 38.8%. In a 2006–2008 Italian study
and a 2009 French study the rate was 46% [5,7]. The highest
mortality in our study was associated with C. glabrata (43.6%)
and C. krusei (57.9%) infections, followed by C. parapsilosis
(36.2%) and C. albicans (36.8%), and lowest with C. tropicalis
(26.8%). This finding contrasts with other studies of cancer
patients in which C. tropicalis is usually associated with the
highest mortality and C. parapsilosis with the lowest overall
mortality [31].
Compared with other studies [5,7], our findings have a lower
case fatality ratio in patients specifically admitted to ICU.
Significantly, risk factors associated with mortality in patients
infected by Candida were species-dependent. MultivariateInfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 87.e1–87.e10
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showed a higher risk of death if the infection was ICU-acquired
(p 0.04) and if CVC was not removed (p 0.02). This was not the
case for ICI with C. glabrata and C. parapsilosis. Patients receiving
total parenteral nutrition and suffering from invasive C. glabrata
infection had a higher risk of death (p 0.01), which was not the
case with C. albicans and C. parapsilosis.
Reasons for these differences need to be explored.
Some limitations of this study must be stressed, in particular
that some questionnaires were incomplete, so information on
severity of IC and complications such as septic shock were not
collected. Also, the mycological analyses of the Candida strains
were not carried out in a single reference laboratory. Hae-
modialysis, which has been acknowledged as a predictor factor
of mortality was not assessed in this study either, due to missing
data.
This ECMM Candida study of surgical patients in ICU pro-
vides significant information on IC in European surgical ICUs.
Candida glabrata was more often isolated after abdominal sur-
gery in patients 60 years, and C. parapsilosis after neurosur-
gery, in patients with multiple trauma as well as in children 1
year of age. This is highly relevant to primary antifungal regi-
mens, given the diverse susceptibility patterns of different
Candida species. With C. glabrata having reduced susceptibility
to fluconazole and C. parapsilosis having reduced susceptibility
to the echinocandins, primary antifungal regimens should be
adjusted to the local epidemiology. The findings in our study
emphasize the importance of establishing continuous national
surveillance programs in each country, as well as in different
patient populations and age groups, so that we may obtain the
background data needed to develop national recommendations.
The physicians also need to seriously consider their antifungal
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